Kenvue Says FDA Has Granted Tylenol Three-Year Exclusivity For New OTC Formulation
KVUE•FDA grants exclusivity for new Tylenol OTC formulation
July 24 (Reuters) - Kenvue Inc KVUE.N:
- FDA approves Tylenol® with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg)
- Kenvue - FDA grants Tylenol three-year exclusivity for new OTC formulation
- Kenvue - Tylenol with Naproxen to be available soon at major U.S. retailers
